PTC Therapeutics (PTC Therapeutics) EV-to-EBIT : -5.82 (As of Apr. 25, 2024)

View and export this data going back to 2013. Start your Free Trial

What is PTC Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, PTC Therapeutics's Enterprise Value is $3,299.0 Mil. PTC Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-566.9 Mil. Therefore, PTC Therapeutics's EV-to-EBIT for today is -5.82.

The historical rank and industry rank for PTC Therapeutics's EV-to-EBIT or its related term are showing as below:

PTCT' s EV-to-EBIT Range Over the Past 10 Years
Min: -43.07 Med: -7.81 Max: 3.48
Current: -5.82

During the past 13 years, the highest EV-to-EBIT of PTC Therapeutics was 3.48. The lowest was -43.07. And the median was -7.81.

PTCT's EV-to-EBIT is ranked worse than
100% of 444 companies
in the Biotechnology industry
Industry Median: 8.05 vs PTCT: -5.82

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. PTC Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $3,438.9 Mil. PTC Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-566.9 Mil. PTC Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -16.49%.

PTC Therapeutics EV-to-EBIT Historical Data

The historical data trend for PTC Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PTC Therapeutics EV-to-EBIT Chart

PTC Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-11.50

-10.31

-5.97

-7.73

-6.07

PTC Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															-7.73	-7.91	-5.84	-3.39	-6.07

Competitive Comparison of PTC Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, PTC Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PTC Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PTC Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where PTC Therapeutics's EV-to-EBIT falls into.

PTC Therapeutics EV-to-EBIT Calculation

PTC Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	3298.994	/	-566.929
	=	-5.82

PTC Therapeutics's current Enterprise Value is $3,299.0 Mil.
PTC Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-566.9 Mil.

PTC Therapeutics (NAS:PTCT) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

PTC Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-566.929	/	3438.921284
	=	-16.49 %

PTC Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $3,438.9 Mil.
PTC Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-566.9 Mil.

PTC Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of PTC Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

PTC Therapeutics (PTC Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PTC Therapeutics Inc (NAS:PTCT) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

BH3:Germany

Address

100 Corporate Court, South Plainfield, NJ, USA, 07080

Website

https://www.ptcbio.com

PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.

Executives

Neil Gregory Almstead	officer: EVP Research Pharma Ops & Tech	C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Matthew B. Klein	officer: Chief Development Officer	C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Mark Elliott Boulding	officer: Exec. VP and CLO	C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Eric Pauwels	officer: Chief Business Officer	550 HILLS DRIVE, BEDMINSTER NJ 07921
Christine Marie Utter	officer: Principal Financial Officer	C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Lee Scott Golden	officer: Chief Medical Officer	17199 N. LAUREL PARK DRIVE, SUITE 401, LIVONIA MI 48152
Michael Schmertzler	director	110 WASHINGTON STREET, SUITE 1300, CONSHOHOCKEN PA 19428
Pierre Gravier	officer: CHIEF FINANCIAL OFFICER	C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Alethia Young	director	C/O GRAPHITE BIO, INC., 201 HASKINS WAY, SUITE 210, SOUTH SAN FRANCISCO CA 94080
Bell William F. Jr.	director	C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Emma Reeve	director	C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
Allan Steven Jacobson	director	PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
David P Southwell	director	C/O INOTEK PHARMACEUTICALS CORPORATION, 91 HARTWELL AVENUE, LEXINGTON MA 02421
Emily Luisa Hill	officer: Chief Financial Officer	C/O PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Stuart Walter Peltz	director, officer: Chief Executive Officer	PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080